Skip to main content
logo
Kyverna Therapeutics, Inc. (KYTX)
NASDAQ: KYTX · Real-Time Price · USD
4.620
-0.540 (-10.47%)
At close: Nov 5, 2026, 4:00 PM EST
4.630
+0.010 (0.22%)
After-hours: Nov 5, 2026, 5:33 PM EST

Kyverna Therapeutics Ratios and Metrics

Millions USD. Fiscal year is Jan - Dec.

Total Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Market Capitalization
286537161---
Market Cap Growth
-3.97%232.60%----
Enterprise Value
119371-151---
Last Close Price
5.169.403.74---

Price Ratios

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PB Ratio
1.922.310.61---
P/TBV Ratio
1.742.310.61---

Financial Efficiency

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Debt / Equity Ratio
0.200.130.030.190.230.09
Net Debt / Equity Ratio
-1.00-1.08-1.04-0.99-0.87-1.13
Net Debt / EBITDA Ratio
1.061.491.980.801.432.74
Net Debt / FCF Ratio
1.051.632.380.911.113.01
Asset Turnover
----0.09-
Quick Ratio
8.757.658.472.904.294.78
Current Ratio
9.067.768.613.064.464.84
Return on Equity (ROE)
-87.24%-64.67%-80.74%-125.95%-52.95%-
Return on Assets (ROA)
-44.51%-35.47%-46.93%-54.89%-24.10%-
Return on Capital Employed (ROCE)
-80.70%-66.00%-52.60%-112.80%-53.50%-37.90%

Yields

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Nov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Earnings Yield
-62.36%-30.04%-78.95%---
FCF Yield
-55.07%-28.62%-72.13%---
Buyback Yield / Dilution
-22.58%-15.46%-5590.81%-47.89%-71.30%-
SEC Filings: 10-K · 10-Q